




































































































































Abstract: Within  the  scenario of an  increasing  life expectancy worldwide  it  is mandatory  to  identify determinants of
healthy aging. Centenarian offspring (CO) is one of the most informative model to identify trajectories of healthy aging and
their determinants  (genetic and environmental), being  representative of elderly  in  their 70th whose  lifestyle can be still
modified to attain a better health. This study is the first comprehensive investigation of the health status of 267 CO (mean
age: 70.2 years) and adopts the  innovative approach of comparing CO with 107 age‐matched offspring of non‐long‐lived
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INTRODUCTION 
 
Centenarians, i.e subjects who reached extreme 
longevity, are an extraordinary model to study human 
longevity and healthy aging [1-4]. However, the study 
of centenarians have some limitations (rarity, lack of an 
age-matched control group and frailty related to 
extreme age). Some of these difficulties can be 
overcome by studying centenarians’ offspring (CO) 
who are one generation (about 20-30 years) younger 
than centenarians and are representative of elderly 
whose lifestyle can be still modified to attain a better 
health. Moreover, CO allow to study both genetic and 
environmental/lifestyle determinants of healthy aging. 
In fact, human longevity seems to cluster in families 
enriched in long-lived parents and ancestors, and 
parents/mothers who later will become centenarians 
likely adopt more healthy lifestyle for their children [5]. 
An impressive and coherent series of epidemiological 
data from different populations (White Americans from 
New England, Mormons from Utah, Ashkenazi Jewish 
living in USA, Icelanders, Japanese from Okinawa, and 
Netherlanders from Leiden) points out the presence of a 
strong familiar and genetic component of human 
longevity. Overall, these studies suggest that relatives 
(parents, siblings and offspring) of long-lived subjects 
have a significant survival advantage, a higher 
probability to have been or to become long-lived and a 
lower risk to undergo to major age-related diseases, 
such as cardio- and cerebral-vascular diseases (CVD), 
diabetes, and cancer [6-17], associated with a 
favourable lipoprotein profile (larger HDL and LDL 
particle size) and increased homozygosity for the 405 
valine allele (V allele) in the CETP gene (Cholesteryl 
Ester Transfer Protein) [18], and the -641 C allele in 
APOC3 gene [19]. Therefore, relatives of centenarians 
and in particular CO represent an informative model to 
study biological and genetic factors involved in human 
healthy aging and longevity. Despite the interest of the 
CO model to study determinants and trajectories of 
healthy aging, a comprehensive and deep 
characterization of the CO phenotype is still lacking. 
Accordingly, we adopted a multidimensional approach 
which integrates functional and cognitive assessment 
together with epidemiological and clinical data, 
including pro- and anti-inflammatory cytokines and 
adipokines, lipid profile, and insulin resistance. 
Moreover, we paid particular attention to the control 
group to be compared with CO. Indeed, at variance with 
previous studies (see Supplemental Table 1) we made 
an effort to recruit unrelated age-matched elderly born 
from non-long lived parents. Indeed, CO were 
compared to age-matched elderly whose parents (both) 
were born in the same birth cohort of centenarians but 
who died before reaching the age threshold over which 
subjects can be classified as long-lived, according to 
strict Italian demographic data [20]. These subjects are 
hereafter indicated as “NCO controls”. Within this 
scenario, the present study aimed at investigating the 
health status of a consistent group of Italian CO using 
for the first time a multidimensional approach 
(epidemiological and clinical data; functional and 
cognitive measures such as ADL, SMMSE, chair stand 
and handgrip strength tests; pro- and anti-inflammatory 
cytokines and adipokines, and major biochemical risk 
factors for age-related diseases) [4,21-28], in 
comparison to a group of unrelated NCO controls 




Table 1 compares the general and anthropometric 
characteristics of CO and NCO controls in the whole 
population and in males and females, separately. CO 
showed higher education level (p=.048 for entire 
population; p=.009 for females) and a lower proportion 
of married individuals, particularly among females 
(p=.001 for entire population; p=.046 for females). Life-
style characteristics were not different between the two 
groups. Intriguingly, significant differences between 
CO and NCO controls emerged from the evaluation of 
anthropometric measurements. In the entire population, 
CO had lower weight (p<.001), smaller waist (p=.003) 
and hip circumferences (p=.061), lower waist/hip ratio 
(p=.014) and lower BMI (p=.002) underlining that they 
were leaner than NCO controls; in fact a lower 
proportion of overweight and obese individuals was 
present within the group of CO (p=.010). The 
waist/height ratio was also significantly lower in CO 
compared to NCO controls (p=.017) despite the two 
groups exhibited the same height. These anthropometric 
traits show a gender distinction. Female CO showed a 
significantly lower weight (p=.001), waist (p=.005) and 
hip (p=.013) circumferences, waist/height ratio 
(p=.016), BMI (p=.006) and a lower proportion of obese 
and overweight subjects (p=.008) in comparison to 
female NCO controls. In contrast, no differences were 
evidenced in males. 
 
Table 2 shows the functional and cognitive status of CO 
and NCO controls. Considering the autonomy and self-
sufficiency a significantly higher proportion of CO was 
completely continent (p=.018), able to walk 500 meters 
(p=.034) and to climb up and down the stairs without 
anyone’s help (p=.002) compared to NCO controls. 
This leads to a lower use of walking aids (such as a 
wheelchair, cane, etc.) in the group of CO (p=.017). The 
distribution of subjects across handgrip strength 
quartiles showed that a higher prevalence of CO was in 
the   first   “best  performing”  quartile   (p=.038)  and  a  
  





































higher proportion of them was able to perform chair 
stand test (p<.001) while, among those who were able, 
the time spent to perform the exercise was not different 
between CO and NCO controls (data not shown). Once 
again, female CO showed a significantly better 
functional status compared to female NCO controls 
(Table 2). On the whole, although both groups are free 
from clinically overt disability, CO were more 
functionally fit than controls.  
 
The scores obtained in the ADL and GDS tests were 
similar between two groups (Table 2) while CO attained 
a better mean score in IADL (p=.040) and SMMSE 
(p=.043).  
 
Table 3 shows the relative prevalence of some age-
related diseases in CO and NCO after adjusting for 
possible confounders such as age, gender, education, 





































valence of stroke/cerebral thrombosis-hemorrhage (- 
80%; p=.022) and a trend towards a lower prevalence of 
cancer (malign: - 47%; p=.071; benign: - 58%; p=.072). 
At the moment of the interview, CO had a significantly 
lower prevalence of hypertension (- 52%; p=.006), 
hypercholesterolemia (- 44%; p=.025) and a marginally 
significant lower prevalence of COPD (- 61%; p=.073) 
and osteoporosis (- 48%; p=.051). CO reported a lower 
prevalence of a series of ailments, such as glaucoma, 
gastritis, prostatic hypertrophy, etc, collectively 
indicated as “other diseases” (- 52%; p=.004).  
 
With regard to the current pharmacological therapy, a 
lower percentage of CO underwent a multi-drug therapy 
with more than 4 drugs (p<.001) when compared to 
NCO controls. In particular, CO were less treated with 
cardiovascular (p=.005), hypotensive (p<.001) and 
lipid-lowering (p<.001) drugs (Table 3).  
Table 1. Demographic, lifestyle and anthropometric features of centenarians’ offspring (CO) and offspring of non‐long‐lived 
parents (NCO) 














Age, mean (SD) 70.2 (6.6) 71.1 (6.0) 0.230 70.2 (6.3) 70.4 (6.3) 0.865 70.2 (6.8) 71.7 (5.7) 0.107 
Education, years, mean 
(SD)  
11.2 (5.0) 10.1 (4.3) 0.048 11.3 (5.2) 10.8 (4.8) 0.608 11.1 (4.9) 9.4 (3.7) 0.009 
Marital Status           
Never married, n (%)  43 (16.1) 3 (2.8) 
0.001 
12 (11.1) 0 (0.0) 
0.058 
31 (19.5) 3 (5.8) 
0.046 
Married, n (%)  159 (59.6) 82 (76.6) 84 (77.8) 48 (87.3) 75 (47.2) 34 (65.4) 
Divorced, n (%)  14 (5.2) 3 (2.8) 6 (5.6) 2 (3.6) 8 (5.0) 1 (1.9) 
Widow/widower, n (%)  51 (19.1) 19 (17.8) 6 (5.6) 5 (9.1) 45 (28.3) 14 (26.9) 
Life-style          
Current smokers, n (%) 38 (14.3) 18 (16.8) 0.544 13 (12.1) 8 (14.5) 0.667 25 (15.8) 10 (19.2) 0.567 
Former smokers, n (%) 102 (45.1) 40 (45.5) 0.959 55 (57.9) 28 (60.9) 0.736 47 (35.9) 12 (28.6) 0.385 
Daily alcohol 
consumption, n (%) 
137 (52.5) 57 (54.3) 0.756 72 (67.9) 35 (64.8) 0.693 65 (41.9) 22 (43.1) 0.880 
Anthropometric 
features  
         
Weight, Kg, mean (SD) 69.7 (13.2) 75.3 (12.8) <0.001 77.0 (12.3) 79.5 (12.4) 0.223 64.6 (11.4) 70.8 (11.8) 0.001 
Height, cm, mean (SD)  161.8 (8.9) 163.6 (8.8) 0.090 168.7 (7.0) 169.0 (6.7) 0.781 157.1 (6.8) 157.7 (6.8) 0.594 
Waist circumference, cm 
mean (SD) 
90.9 (13.0) 95.3 (11.4) 0.003 97.2 (10.8) 98.0 (10.1) 0.651 86.6 (12.6) 92.3 (12.0) 0.005 
Hip circumference, cm 
mean (SD) 
103.4 (10.1) 105.5 (8.8) 0.061 103.5 (8.8) 103.5 (8.0) 0.969 103.4 
(10.8) 
107.6 (9.2) 0.013 
Waist/hip, mean (SD) 0.88 (0.1) 0.90 (0.1) 0.014 0.94 (0.06) 0.9 (0.06) 0.610 0.84 (0.07) 0.86 (0.07) 0.070 
Waist/height, mean (SD) 0.56 (0.08) 0.58 (0.07) 0.017 0.58 (0.06) 0.58 (0.06) 0.691 0.55 (0.09) 0.59 (0.08) 0.016 
BMI, Kg/m2, mean (SD) 26.5 (4.4) 28.1 (4.2) 0.002 26.9 (3.5) 27.8 (3.9) 0.125 26.3 (5.0) 28.5 (4.5) 0.006 
Normal (BMI<25), n (%) 103 (39.5) 24 (22.9) 
0.010 
34 (32.1) 14 (25.5) 
0.647 
69 (44.5) 10 (20.0) 
0.008 Overweight (25≤BMI<30), n (%) 
109 (41.8) 54 (51.4) 53 (50.0) 29 (52.7) 56 (36.1) 25 (50.0) 



































































































































sufficiency          
ADL 5 items, mean (SD) 5 (0.1) 4.9 (0.6) 0.127 5 (0.0) 5.0 (0.3) 0.322 5.0 (0.0) 4.8 (0.8) 0.197 
Completely continent, n 
(%) 240 (90.2) 87 (81.3) 0.018 99 (92.5) 50 (90.9) 0.720 141 (88.7) 37 (71.2) 0.003 
IADL, mean (SD) 7.9 (0.5) 7.7 (1.1) 0.040 7.9 (0.4) 7.7 (0.9) 0.169 7.9 (0.6) 7.7 (1.3) 0.163 
Ability to walk 500 
meters, n (%) 254 (95.5) 95 (89.6) 0.034 107 (99.1) 53 (96.4) 0.223 147 (93.0) 42 (82.4) 0.024 
Ability to go up and 
down the stairs, n (%) 228 (85.4) 76 (71.7) 0.002 101 (93.5) 47 (85.5) 0.144 127 (79.9) 29 (56.9) 0.001 
Use of aids, n (%) 9 (3.4) 10 (9.4) 0.017 2 (1.9) 4 (7.3) 0.181 7 (4.4) 6 (11.8) 0.058 
Handgrip strength test          
1st quartile, n (%) 70 (26.8) 18 (17.1) 
0.038 
25 (23.1) 15 (27.8) 
0.103 
45 (29.4) 3 (5.9) 
0.007 
2nd quartile, n (%) 64 (24.5) 19 (18.1) 28 (25.9) 5 (9.3) 36 (23.5) 14 (27.5) 
3rd quartile, n (%) 69 (26.4) 37 (35.2) 31 (28.7) 19 (35.2) 38 (24.8) 18 (35.3) 
4th quartile, n (%) 58 (22.2) 31 (29.5) 24 (22.2) 15 (27.8) 34 (22.2) 16 (31.4) 
Ability to perform chair 
stand test, n (%) 251 (96.2) 87 (84.5) <0.001 103 (97.2) 46 (88.5) 0.027 148 (95.5) 41 (80.4) 0.002 
Cognitive function          
SMMSE, mean (SD) 29.0 (1.5) 28.6 (2.5) 0.043 29.1 (1.2) 28.9 (1.3) 0.360 29.0 (1.7) 28.3 (3.3) 0.145 
Mood          




 N CO N NCO OR (95% CI) p-value 
Past diseases       
Pneumonia, n (%) 267 65 (24.3) 106 22 (20.8) 1.277 (0.723 - 2.254) 0.400 
Myocardial Infarction, n (%) 267 12 (4.5) 106 12 (11.3) 0.489 (0.201 - 1.194) 0.116 
Stroke, cerebral thrombosis-haemorrhage, n 
(%) 266 4 (1.5) 105 8 (7.6) 0.200 (0.051 - 0.789) 0.022 
Malign tumor, n (%) 267 26 (9.7) 106  18 (17.0) 0.533 (0.269 - 1.056) 0.071 
Benign tumor, n (%) 267 11 (4.1) 106 10 (9.4) 0.419 (0.162 - 1.083) 0.072 
Hip fracture, n (%) 267 5 (1.9) 106 4 (3.8) 0.535 (0.136 - 2.113) 0.372 
Spinal collapse, n (%) 267 8 (3.0) 106 6 (5.7) 0.404 (0.122 - 1.336) 0.137 
Current diseases       
Heart failure, n (%) 267 2 (0.7) 106 4 (3.8) 0.276 (0.047 - 1.611) 0.153 
Irregular heart rhythm, n (%) 267 29 (10.9) 107 20 (18.7) 0.584 (0.301 - 1.131) 0.110 
Hypertension, n (%) 267 109 (40.8) 107 68 (63.6) 0.485 (0.288 - 0.816) 0.006 
COPD, n (%) 267 9 (3.4) 106 9 (8.5) 0.394 (0.143 - 1.089) 0.073 
Dementia, n (%)  267 0 (0.0) 106 1 (0.9) na na 
Depression/Anxiety, n (%) 267 41 (15.4) 106 22 (20.8) 0.669 (0.362 - 1.239) 0.201 
Osteoporosis, n (%) 267 44 (16.5) 106 24 (22.6) 0.520 (0.270 - 1.002) 0.051 
Diabetes, n (%) 267 26 (9.7) 106 12 (11.3) 1.042 (0.462 - 2.352) 0.921 
Hypothyroidism, n (%) 267 25 (9.4) 106 8 (7.5) 0.988 (0.400 - 2.437) 0.979 
Hyperthyroidism, n (%) 267 3 (1.1) 106 4 (3.8) 0.290 (0.053 - 1.593) 0.154 
Hypercholesterolemia, n (%) 267 91 (34.1) 106 46 (43.4) 0.563 (0.342 - 0.929) 0.025 
Chronic renal insufficiency, n (%) 267 3 (1.1) 106 5 (4.7) 0.273 (0.052 - 1.423) 0.123 
aOther diseases, n (%) 265 85 (32.1) 107 53 (49.5) 0.484 (0.296 - 0.793) 0.004 
Drugs use, n (%)       
0 drugs, n (%) 267 58 (21.7) 106 7 (6.6) 1  
1-3 drugs, n (%) 267 148 (55.4) 106 48 (45.3) 0.375 (0.156 - 0.897) 0.028 
4 or more drugs, n (%) 267 61 (22.8) 106 51 (48.1) 0.136 (0.053 - 0.347) <0.001 
Cardiovascular Therapy, n (%) 267 54 (20.2) 106 36 (34.0) 0.493 (0.299 - 0.813) 0.005 
Hypotensive Therapy, n (%) 267 106 (39.7) 106 68 (64.2) 0.368 (0.231 - 0.587) <0.001 
Antidiabetic Therapy, n (%) 267 15 (5.6) 106 10 (9.4) 0.571 (0.248 - 1.316) 0.188 
Lipid-lowering Therapy, n (%) 267 47 (17.6) 106 40 (37.7) 0.353 (0.213 - 0.583) <0.001 
Prevalence of past and current diseases was adjusted for age, gender, education, marital status and BMI.  a The following conditions are included: prostatic 
hypertrophy, cataract and glaucoma, gastritis, hiatus hernia, cholelithiasis, allergies, hemicranias, haemorrhoids, etc. na: not assessed. 
  
































Table 4 shows conventional CVD risk factors, 
metabolic and inflammatory mediators in CO and NCO 
controls. CO had higher levels of total (p=.037) and 
LDL (p=.003) cholesterol, and lower levels of HDL 
cholesterol (p=.019) with a consequent worse total/HDL 
cholesterol ratio (p=.001) showing an apparently 
unfavourable lipid profile in comparison to NCO 
controls. Other risk factors, such as triglycerides and 
inflammatory markers like CRP, A-SAA, and IL-6, as 
well as levels of adiponectin, leptin, resistin and TNF-α 
did not change between CO and NCO controls (Table 
4). Finally, glycaemia, insulin and insulin resistance 
index (HOMA-IR index) were similar between the two 
groups. Analyzing thyroid hormones, we observed that 
CO had a significantly lower levels of free thyroxin 




Human longevity clusters in families enriched in long-
lived parents and ancestors. Several studies were 
concordant in indicating that CO have a longer survival 
and are significantly healthier compared with age-
































informative model to study the determinants of healthy 
aging and longevity [7-9]. Our data show that Italian  
CO have a better functional and cognitive fitness 
(higher IADL and SMMSE scores; ability of walking 
500 meter; going up and down the stairs; performing 
Chair Stand test; displaying higher grip strength) and 
were leaner than controls in terms of weight, hip 
circumference, BMI, overweight and obesity 
prevalence, confirming previous findings in CO living 
in non-European countries (e.g. USA) [7] and belonging 
to a different ethnicity (Ashkenazi Jewish) [10]. Our 
new data on central adiposity (waist circumference, 
waist/hip ratio and waist/height ratio) give further 
support to the notion that CO do have a peculiar body 
anthropometrical characteristics which emerged in all 
the different cohorts so far examined. Central adiposity 
is a strong predictors of cardiovascular diseases (CVD) 
and mortality risk [29-33]. Our data and those of 
previous studies suggest that being leaner and having 
less visceral adiposity at age 70 is likely a strong 
contributor to the better health status of CO, in 
comparison to NCO. The animal model counterpart of 
this observation in humans is represented by data 
showing that ad libitum-fed rats with selective removal 
Table 4. Functional and cognitive status of centenarians’ offspring  (CO) and offspring of non‐long‐lived 
parents (NCO) 
 CO  N=266 
NCO 
N=105 p-value 
Conventional Risk Factors    
Total cholesterol, mg/dl 203.0 (177.0 – 231.0) 195.0 (171.5 – 217.0) 0.037 
LDL cholesterol, mg/dl  119.3 (98.2 – 150.0) 112.0 (88.0 – 135.6) 0.003 
HDL cholesterol, mg/dl  51.0 (42.0 – 63.0) 56.0 (45.5 – 74.0) 0.019 
Total/HDL cholesterol ratio  4.0 (3.1 – 4.8) 3.4 (2.7 – 4.2) 0.001 
Triglycerides, mg/dl 111.5 (86.0 – 156.0) 104.5 (79.0 – 146.0) 0.175 
Albumin, mg/dl 4.2 (3.4 – 4.5) 4.1 (3.4 – 4.4) 0.445 
CRP, mg/L  1.3 (0.8 – 3.0) 1.6 (0.8 – 3.2) 0.341 
A-SAA protein, mg/ml 92.0 (44.9 -197.3) 85.3 (50.7 – 177.7) 0.959 
IL-6, pg/ml 16.7 (10.0 – 34.0) 19.1 (10.9 – 31.4) 0.500 
Metabolic mediators    
Adiponectin, µg/ml 34.0 (19.3 – 56.3) 30.6 (18.3 – 56.4) 0.496 
Leptin, ng/ml 14.3 (7.3 – 31.8) 14.3 (6.7 – 32.4) 0.991 
Resistin, ng/ml 9.2 (7.0 – 12.2) 9.1 (7.0 – 12.4) 0.964 
TNF-α, pg/ml 10.3 (2.8 – 31.9) 11.0 (3.8 – 31.5) 0.655 
Insulin resistance markers    
Glycaemia, mmol/L 4.8 (4.4 – 5.4) 4.9 (4.6 – 5.5) 0.095 
Insulin, µIUg/ml 10.4 (6.2 – 14.9) 10.5 (6.9 – 14.1) 0.704 
HOMA-IR index  2.2 (1.3 – 3.5) 2.5 (1.5 – 3.6) 0.393 
aThyroid Hormones    
Free triiodothyronine (FT3), pg/ml  3.0 (2.8 – 3.3) 3.0 (2.8 – 3.3) 0.922 
Free thyroxin (FT4), ng/ml  11.5 (10.4 – 12.6) 11.9 (10.9 – 12.8) 0.033 
TSH, mIU/ml 1.8 (1.3 – 2.5) 1.8 (1.3 – 2.4) 0.798 
T3/T4 ratio 0.3 (0.2 – 0.3) 0.3 (0.2 – 0.3) 0.101 
a Subjects under thyroid therapy were excluded from the analysis. Data are expressed as median (min-max) between parenthesis. 
p-value was derived from Mann-Whitney test. 
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of visceral fat had a significant increase in mean and 
maximum lifespan and a significant reduction in the 
incidence of severe renal diseases compared to ad 
libitum-fed rats without visceral fat removal [34]. On 
the whole, the data in humans and animal model are 
concordant in supporting the notion that fat mass 
reduction, mainly visceral fat, may be one of the 
possible anti-aging mechanisms able to modulate 
mammalian longevity [34]. On the contrary, a great 
number of cross-sectional and longitudinal studies 
indicate that weight gain, increased BMI and obesity 
contribute to a decline in physical and cognitive activity 
[35-37], and that a poor performance in Chair Stand 
tests and the loss of muscle strength are associated with 
adverse health outcomes in older persons [38-40].  
 
An increase in body fat, particularly visceral fat and 
high BMI have been associated with insulin resistance 
[41-42], higher risk for diabetes, cardiovascular disease 
[43], hypertension and metabolic disorders [44]. 
Consistently, we found that Italian CO not only showed 
a better physical status, but had a lower prevalence of 
pathological conditions (myocardial infarction, stroke, 
cerebral thrombosis/hemorrhage, arrhythmia and 
hypertension) than NCO controls, as previously 
reported in New England and Ashkenazi population 
[7,10]. These findings are supported by data regarding 
pharmacological therapy. Italian CO used fewer drugs 
and a lower percentage of them was under 
cardiovascular, hypotensive and lipid-lowering therapy 
compared to NCO controls. The reduced number of CO 
under pharmacological therapy could explain their 
apparent unfavorable lipid profile (higher levels of total 
and LDL cholesterol, total/HDL cholesterol ratio and 
lower levels of HDL cholesterol) in comparison to NCO 
controls. However, it is worth noting that the values 
reported for CO are within the normal range and are not 
indicative of CVD risk. At variance with a previous 
study [8,10], the prevalence of diabetes in Italian CO 
was similar to that of NCO controls. We surmise that 
differences regarding environmental and 
anthropological context, cultural habits and lifestyle 
factors (e.g. diet) between Italian CO and those living in 
other continents (USA) and belonging to different 
ethnicities (Ashkenazi Jewish) may be largely 
responsible for this apparent discrepancy.  
 
One of the major features of the aging process is the 
presence of a chronic low-grade inflammatory status 
(inflammaging) which contributes to the development 
of different pathological conditions [28,45-49]. This 
peculiar inflammatory activity, leading to long-term 
tissue damage has been found to be related to mortality 
risk for all causes in older persons [50]. In this study, 
parameters related to inflammaging were similar 
between CO and NCO controls, suggesting that 
significant differences might appear later in life, and 
longitudinal studies are needed to clarify this point. 
 
CO obtained higher scores in the handgrip test 
compared to controls. In a previous work conducted on 
the same subjects, we observed lower levels of IGF-1 in 
CO in comparison to NCO [51]. Data from the present 
paper highlighted that, although having lower levels of 
IGF-1, CO did not show the typical negative aspects 
related to a low IGF-1 levels in elderly such as loss of 
muscle mass and power [52] and higher risk of CVD 
[53-54]. Therefore, the role of this potent anabolic 
hormone in the genesis of the aging phenotype remains 
controversial and its complex function during specific 
stages of the life span should be deeply explored 
[51,55].  
 
Several changes in thyroid function are frequently 
observed in the elderly and some studies have shown 
that centenarians and their relatives have reduced levels 
of FT3, FT4 and TSH [56,57]. Findings of this study 
did not show any significant difference between CO and 
NCO in the levels of FT3, TSH thyroid hormones and 
in T3/T4 ratio. The levels of FT4 appear significantly 
lower in CO, but the difference is not so relevant to 
have a biological meaning. The subtle thyroid 
hypofunction reported in literature may onset in more 
advanced decades of life in CO as an adaptive 
mechanism to reset the hormonal milieu favouring 
successful ageing and longevity. 
 
This study has several strengths. First of all, the peculiar 
experimental model including centenarians’ offspring 
and age-matched offspring of non-long-lived parents 
born in the same cohort of centenarians. It is worth 
noting that, in comparison with other papers, in this 
study, controls are selected with a more accurate 
method envisaging strict demographic criteria. 
However, even if the identification and the recruitment 
of offspring of both non-long-lived parents was very 
demanding, the size of the cohort studied is fully 
comparable to previous researches (see Supplemental 
Table 1). Secondly, all participants have been well 
characterized: medical history was accurately 
documented and several anthropometric, inflammatory 
and metabolic parameters were assessed concomitantly 
to provide a comprehensive picture of their health 
status, from a molecular level (for example through the 
evaluation of inflammatory and metabolic mediators) to 
a systemic/organism level (for example through the 
evaluation of the ability to perform physical tests). This 
is worthwhile, since the aging process differently affects 
each organ of the body and also every tissue and cell 
type composing the organ, giving rise to the so-called 
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“aging mosaic” [58]. Therefore, in order to disentangle 
the complexity of the aging process it is necessary to 




Since centenarians’ offspring emerged as an excellent 
model to study human aging and longevity, longitudinal 
studies are mandatory to better understand their 
diseases’ susceptibility and outcomes. Moreover, even 
if centenarians’ offspring and controls have been 
recruited in the same geographic area and we can 
suppose they followed a similar diet, the evaluation of 
dietary habits will be essential in future studies. In fact, 
dietary behavior and nutrients intake have been 
associated with occurrence, development and outcomes 
of major age-related diseases having a role in 
determining the overall health status of elderly people 
impinging upon inflammation, oxidative stress and gut 




Study design and participants. A total of 374 subjects 
were enrolled in five Italian cities (Bologna, Milan, 
Florence, Parma and Palermo) and surrounding areas. 
The group of CO consisted of 267 subjects [n=108 
males, mean age (SD) = 70.2 (6.3) years and n=159 
females, mean age (SD) = 70.2 (6.8) years], having a 
centenarian parent born between 1900-1908. The group 
of NCO controls consisted of 107 age-matched 
offspring [n=55 males, mean age (SD) = 70.4 (6.3) 
years and n=52 females, mean age (SD) = 71.7 (5.7) 
years], having both parents born in the same birth 
cohort of centenarians (1900-1908), but dead before the 
threshold age over which subjects were classified “long-
lived” as previously described [20].  
 
The lists of centenarians and their offspring (CO) were 
obtained by the Register Office, while the offspring of 
non-long-lived parents (NCO) were identified by 
checking the birth and death dates of their parents in 
paper population records from Registers Office. All 
participants signed the informed consent before 
undergoing the questionnaires, measurements and blood 
sampling. The study protocol was approved by the 
Ethical Committee of Sant’Orsola-Malpighi University 
Hospital (Bologna, Italy).  
 
Measurement tools. Anthropometric measures were 
performed while participants wore light dresses and no 
shoes. Body weight was measured using the balance 
SECA Mod. 761 calibrated in kilograms. Height was 
measured with the subject standing barefoot with feet 
together, using an anthropometer calibrated in 
centimeters. Waist circumference was measured using a 
flexible steel tape at the end of exhalation, by wrapping 
the tape at the level of the iliac crest and umbilicus, with 
the subject standing [59]. Hip circumference was 
measured at the level of maximal protrusion of the 
gluteal muscles. Waist-hip ratio was calculated as the 
ratio of waist circumference to hip circumference. 
Waist-height ratio was calculated as the ratio of waist 
circumference to standard height. Body mass index 
(BMI) was calculated as weight in kilograms divided by 
the square of height in meters (kg/m2).  
 
Functional status was assessed by ADL-Activities of 
Daily Living scale (scores ranging from 0 [all functions 
lost] to 5 [all functions preserved]) [60]. Continence 
was analyzed separately [61]. Ability in home 
management was assessed by IADL-Instrumental 
Activities of Daily Living scale (scores ranging from 0 
[all functions lost] to 8 [all functions preserved]) [62].  
Physical performance was assessed by self-reported 
data regarding the ability to walk 500 meters, to go up 
and down the stairs and the use of aids. Handgrip 
Strength Test and Chair Stand Test were performed, the 
former to measure the maximum isometric strength of 
the hand and forearm muscles and the latter to evaluate 
leg strength and endurance measuring the time it takes 
to perform 5 repetitions of sit-to-stand [63]. Handgrip 
strength was measured using a hand-held dynamometer 
(SMEDLYS’ dynamometer, Scandidact, Kvistgaard, 
Denmark) for two performances with each hand. The 
best performance was selected for the analysis and 
scores were divided into quartiles distinguishing 
between men and women. The first quartile included the 
“best-performing” participants. Regarding the Chair 
Stand Test, participants were divided into two groups 
(able or unable to complete the test). Cognitive status 
was assessed by SMMSE-Standardized Mini-Mental 
State Examination test [64] and scores were adjusted by 
age and education according to Magni [65]. Mood was 
investigated by GDS-Geriatric Depression Scale short 
form (15 items) [66]. History of past and current 
diseases was accurately collected by checking the 
participants' medical documentation and addressing the 
major age-related pathologies: pneumonia, myocardial 
infarction, stroke/cerebral thrombosis-hemorrhage, 
cancer, benign tumor, hip fracture, spinal collapse, heart 
failure, cardiac arrhythmia, high blood pressure, chronic 
obstructive pulmonary disease (COPD), dementia, 
depression/anxiety, osteoporosis, diabetes mellitus, 
hypo and hyperthyroidism, hypercholesterolemia and 
chronic renal insufficiency.  
 
Current use of medication (including inspection of the 
drugs by the interviewer) was recorded and drugs 
grouped in 4 main therapies: cardiovascular (anti-
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arrhythmic and/or vasodilatator and/or thrombolytic 
drugs), hypotensive (calcium channel blockers and/or 
ACE inhibitors and/or diuretics and/or beta blockers), 
antidiabetic (sulfonylureas and/or biguanides and/or 
insulin and insulin analogues and/or other oral 
antidiabetic association), and lipid-lowering (statins 
and/or fibrates and/or other hypolipidemic agents) 
therapy. 
 
Laboratory measurements. Overnight fasting blood 
samples were obtained in the morning. Serum was 
obtained after clotting and centrifugation at 760 g for 20 
min at 4°C, rapidly frozen and stored at −80°C. Plasma 
was obtained within 2 hours from venipuncture by 
centrifugation at 2000 g for 20 min at 4°C, rapidly 
frozen and stored at −80°C. Serum total and HDL 
cholesterol, triglycerides, C-Reactive Protein (CRP), 
glycaemia and thyroid hormones were measured by 
standard biochemical assays. The concentration of 
serum LDL was calculated by using the Friedewald 
equation: LDL = total cholesterol – HDL – 
(triglycerides/5). Serum insulin was measured by a 
chemiluminescent immunoassay (LIAISON® Insulin 
assay, DiaSorin, Saluggia, Italy) and analyzed by the 
LIAISON® Analyzer. Insulin resistance status was 
assessed as homeostasis model assessment of insulin 
resistance (HOMA-IR) according to the following 
formula [67]: insulin (μU/mL) x glucose (mmol/L) / 
22.5. Plasma levels of IL-6, IL-10, TNF-α, serum 
amyloid A (A-SAA), adiponectin, leptin, and resistin 
were measured by multiplex sandwich ELISA 
technology (SearchLight, Aushon Biosystems, Billerica, 
MA) according to the manufacturer’s instructions. 
Samples, standards, and reagents were dispensed by a 
standardized technique employing a robotic liquid 
handling system with 16 channels (Microlab® STAR, 
Hamilton Robotics, Reno, NV). Plasma TGF-β1 levels 
were determined by ELISA using a commercial kit 
(DRG Instruments GmbH, Marburg, Germany) 
according to the manufacturer’s instructions and 
concentration of TGF-β1 was detected and quantified 
by a SynergyTM HT Multi-Detection Microplate 
Reader (Bio-Tek® Instruments, Winooski, VT). 
Subjects who used medication that could influence the 
inflammatory status, such as steroid or nonsteroidal 
anti-inflammatory drugs and immunomodulant agents, 
during the week before blood drawn were excluded 
from adipokines and cytokines analysis.  
 
Statistical analysis. Demographic, lifestyle, anthropo-
metric features and functional, cognitive, perceived 
health status as well as inflammatory status were 
examined in the two groups of subjects by univariate 
statistics (Independent samples t-test or Mann-Whitney 
U test, Chi-square test or Fisher's exact test) for 
continuous and categorical variables as appropriate. The 
dichotomous dependent variables were analyzed with 
logistic regression models and the odds ratio (OR) with 
95% confidence interval was used as a measure of 
association. The regression model was adjusted for the 
effects of age, gender, education, marital status and 
BMI. All analyses were executed using SPSS 15.0 for 
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